FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablet (Opana ER, Endo).

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

FDA warns of serious blood disorder resulting from abuse of Opana ER

Newsletter